A prospective study of venous thromboembolism in relation to factor V Leiden and related factors

Aaron R. Folsom, Mary Cushman, Michael Y. Tsai, Nena Aleksic, Susan R. Heckbert, Lori L. Boland, Albert W. Tsai, Norbert Yanez, Wayne D. Rosamond

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

The aim of this study was to examine the occurrence of venous thromboembolism (VTE) in relation to factor V-related risk factors. Using a nested case-control design combining 2 population-based prospective studies, we measured factor V Leiden, HR2 haplotype, activated protein C (APC) resistance, and plasma factor V antigen in 335 participants who developed VTE during 8 years of follow-up and 688 controls. The overall odds ratio (OR) of VTE was 3.67 (95% Cl, 2.20-6.12) in participants carrying factor V Leiden compared with noncarriers. APC resistance measured after predilution with factor V-deficient plasma conferred an OR of 2.58 (95% Cl, 1.62-4.10). All 3 participants homozygous for the HR2 haplotype had a VTE, and the OR of VTE for homozygosity was estimated to be 5.5 (95% Cl, 2.45-12.5). Carriers of the HR2 haplotype otherwise were not at increased risk of VTE overall (OR = 1.05; 95% Cl, 0.64-1.72), but double heterozygotes for HR2 and factor V Leiden carried an OR of idiopathic VTE of 16.3 (95% Cl, 1.7-159) compared with noncarriers. Factor V antigen also was not associated with VTE overall, but for participants with the combination of high factor V antigen plus factor V Leiden the OR of idiopathic VTE was 11.5 (95% Cl, 4.2-31.4). In the general population, APC resistance and factor V Leiden were important VTE risk factors; homozygosity for the HR2 haplotype may be a risk factor but was rare; otherwise, HR2 haplotype and factor V antigen were not risk factors except in carriers of factor V Leiden.

Original languageEnglish (US)
Pages (from-to)2720-2725
Number of pages6
JournalBlood
Volume99
Issue number8
DOIs
StatePublished - Apr 15 2002
Externally publishedYes

Fingerprint

Factor V
Venous Thromboembolism
Prospective Studies
Protein C
Haplotypes
Odds Ratio
Antigens
Activated Protein C Resistance
R Factors
Plasmas
factor V Leiden
Heterozygote
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Folsom, A. R., Cushman, M., Tsai, M. Y., Aleksic, N., Heckbert, S. R., Boland, L. L., ... Rosamond, W. D. (2002). A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood, 99(8), 2720-2725. https://doi.org/10.1182/blood.V99.8.2720

A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. / Folsom, Aaron R.; Cushman, Mary; Tsai, Michael Y.; Aleksic, Nena; Heckbert, Susan R.; Boland, Lori L.; Tsai, Albert W.; Yanez, Norbert; Rosamond, Wayne D.

In: Blood, Vol. 99, No. 8, 15.04.2002, p. 2720-2725.

Research output: Contribution to journalArticle

Folsom, AR, Cushman, M, Tsai, MY, Aleksic, N, Heckbert, SR, Boland, LL, Tsai, AW, Yanez, N & Rosamond, WD 2002, 'A prospective study of venous thromboembolism in relation to factor V Leiden and related factors', Blood, vol. 99, no. 8, pp. 2720-2725. https://doi.org/10.1182/blood.V99.8.2720
Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 2002 Apr 15;99(8):2720-2725. https://doi.org/10.1182/blood.V99.8.2720
Folsom, Aaron R. ; Cushman, Mary ; Tsai, Michael Y. ; Aleksic, Nena ; Heckbert, Susan R. ; Boland, Lori L. ; Tsai, Albert W. ; Yanez, Norbert ; Rosamond, Wayne D. / A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. In: Blood. 2002 ; Vol. 99, No. 8. pp. 2720-2725.
@article{9248b2cca97f4eb9ad4bc8a86de7d9db,
title = "A prospective study of venous thromboembolism in relation to factor V Leiden and related factors",
abstract = "The aim of this study was to examine the occurrence of venous thromboembolism (VTE) in relation to factor V-related risk factors. Using a nested case-control design combining 2 population-based prospective studies, we measured factor V Leiden, HR2 haplotype, activated protein C (APC) resistance, and plasma factor V antigen in 335 participants who developed VTE during 8 years of follow-up and 688 controls. The overall odds ratio (OR) of VTE was 3.67 (95{\%} Cl, 2.20-6.12) in participants carrying factor V Leiden compared with noncarriers. APC resistance measured after predilution with factor V-deficient plasma conferred an OR of 2.58 (95{\%} Cl, 1.62-4.10). All 3 participants homozygous for the HR2 haplotype had a VTE, and the OR of VTE for homozygosity was estimated to be 5.5 (95{\%} Cl, 2.45-12.5). Carriers of the HR2 haplotype otherwise were not at increased risk of VTE overall (OR = 1.05; 95{\%} Cl, 0.64-1.72), but double heterozygotes for HR2 and factor V Leiden carried an OR of idiopathic VTE of 16.3 (95{\%} Cl, 1.7-159) compared with noncarriers. Factor V antigen also was not associated with VTE overall, but for participants with the combination of high factor V antigen plus factor V Leiden the OR of idiopathic VTE was 11.5 (95{\%} Cl, 4.2-31.4). In the general population, APC resistance and factor V Leiden were important VTE risk factors; homozygosity for the HR2 haplotype may be a risk factor but was rare; otherwise, HR2 haplotype and factor V antigen were not risk factors except in carriers of factor V Leiden.",
author = "Folsom, {Aaron R.} and Mary Cushman and Tsai, {Michael Y.} and Nena Aleksic and Heckbert, {Susan R.} and Boland, {Lori L.} and Tsai, {Albert W.} and Norbert Yanez and Rosamond, {Wayne D.}",
year = "2002",
month = "4",
day = "15",
doi = "10.1182/blood.V99.8.2720",
language = "English (US)",
volume = "99",
pages = "2720--2725",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - A prospective study of venous thromboembolism in relation to factor V Leiden and related factors

AU - Folsom, Aaron R.

AU - Cushman, Mary

AU - Tsai, Michael Y.

AU - Aleksic, Nena

AU - Heckbert, Susan R.

AU - Boland, Lori L.

AU - Tsai, Albert W.

AU - Yanez, Norbert

AU - Rosamond, Wayne D.

PY - 2002/4/15

Y1 - 2002/4/15

N2 - The aim of this study was to examine the occurrence of venous thromboembolism (VTE) in relation to factor V-related risk factors. Using a nested case-control design combining 2 population-based prospective studies, we measured factor V Leiden, HR2 haplotype, activated protein C (APC) resistance, and plasma factor V antigen in 335 participants who developed VTE during 8 years of follow-up and 688 controls. The overall odds ratio (OR) of VTE was 3.67 (95% Cl, 2.20-6.12) in participants carrying factor V Leiden compared with noncarriers. APC resistance measured after predilution with factor V-deficient plasma conferred an OR of 2.58 (95% Cl, 1.62-4.10). All 3 participants homozygous for the HR2 haplotype had a VTE, and the OR of VTE for homozygosity was estimated to be 5.5 (95% Cl, 2.45-12.5). Carriers of the HR2 haplotype otherwise were not at increased risk of VTE overall (OR = 1.05; 95% Cl, 0.64-1.72), but double heterozygotes for HR2 and factor V Leiden carried an OR of idiopathic VTE of 16.3 (95% Cl, 1.7-159) compared with noncarriers. Factor V antigen also was not associated with VTE overall, but for participants with the combination of high factor V antigen plus factor V Leiden the OR of idiopathic VTE was 11.5 (95% Cl, 4.2-31.4). In the general population, APC resistance and factor V Leiden were important VTE risk factors; homozygosity for the HR2 haplotype may be a risk factor but was rare; otherwise, HR2 haplotype and factor V antigen were not risk factors except in carriers of factor V Leiden.

AB - The aim of this study was to examine the occurrence of venous thromboembolism (VTE) in relation to factor V-related risk factors. Using a nested case-control design combining 2 population-based prospective studies, we measured factor V Leiden, HR2 haplotype, activated protein C (APC) resistance, and plasma factor V antigen in 335 participants who developed VTE during 8 years of follow-up and 688 controls. The overall odds ratio (OR) of VTE was 3.67 (95% Cl, 2.20-6.12) in participants carrying factor V Leiden compared with noncarriers. APC resistance measured after predilution with factor V-deficient plasma conferred an OR of 2.58 (95% Cl, 1.62-4.10). All 3 participants homozygous for the HR2 haplotype had a VTE, and the OR of VTE for homozygosity was estimated to be 5.5 (95% Cl, 2.45-12.5). Carriers of the HR2 haplotype otherwise were not at increased risk of VTE overall (OR = 1.05; 95% Cl, 0.64-1.72), but double heterozygotes for HR2 and factor V Leiden carried an OR of idiopathic VTE of 16.3 (95% Cl, 1.7-159) compared with noncarriers. Factor V antigen also was not associated with VTE overall, but for participants with the combination of high factor V antigen plus factor V Leiden the OR of idiopathic VTE was 11.5 (95% Cl, 4.2-31.4). In the general population, APC resistance and factor V Leiden were important VTE risk factors; homozygosity for the HR2 haplotype may be a risk factor but was rare; otherwise, HR2 haplotype and factor V antigen were not risk factors except in carriers of factor V Leiden.

UR - http://www.scopus.com/inward/record.url?scp=0037089315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037089315&partnerID=8YFLogxK

U2 - 10.1182/blood.V99.8.2720

DO - 10.1182/blood.V99.8.2720

M3 - Article

VL - 99

SP - 2720

EP - 2725

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -